<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02298335</url>
  </required_header>
  <id_info>
    <org_study_id>NJCT-1401</org_study_id>
    <nct_id>NCT02298335</nct_id>
  </id_info>
  <brief_title>Glucocorticoid in Treatment of Adult Idiopathic Nephrotic Syndrome：a Prospective Observational Study</brief_title>
  <official_title>A Prospective Observational Study to Assess the Efficacy an Safety of Glucocorticoid Therapy in the Treatment of Adult Idiopathic Nephrotic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess the efficacy and safety of 8-weeks full-dose induction protocol&#xD;
      (prednisone 1mg/kg, maximum 60mg/day) and protracted tapering protocol in the treatment of&#xD;
      adult idiopathic nephrotic syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In full-dose induction period, patients scheme to visit at the 4th and 8th week, and in&#xD;
      protracted tapering period at 10th , 22nd, 42nd and 66th week. If the patients reach complete&#xD;
      remission within 4 weeks, prednisone may be decreased at the 6th week, otherwise keep on the&#xD;
      course to the 8th week. All patients reach complete remission will shift to protracted&#xD;
      tapering period and follow up until prednisone withdrawal, except the cases that relapse and&#xD;
      drop out the study. If proteinuria reappears in someone, angiotensin-converting enzyme&#xD;
      inhibitor（ACEI） or angiotensin receptor blocker（ARB） will be considered combination, on the&#xD;
      premise of the blood pressure is affordable.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 13, 2014</start_date>
  <completion_date type="Actual">October 22, 2020</completion_date>
  <primary_completion_date type="Actual">July 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the cumulative complete remission rate of 8-weeks full-dose induction protocol</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the relapse rate of complete remission participants protracted tapering protocol</measure>
    <time_frame>66 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">235</enrollment>
  <condition>Nephrotic Syndrome，Idiopathic</condition>
  <arm_group>
    <arm_group_label>prednisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First,full-dose induction period, then protracted tapering period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <description>Full-dose induction period: Prednisone 1mg/kg.day, maximum 60mg/day, orally, divided into 3 times; Protracted tapering period: orally, no ask for fract. dos.</description>
    <arm_group_label>prednisone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who signed written informed consent form&#xD;
&#xD;
          -  Age between 18-65 years, female or male&#xD;
&#xD;
          -  Patients with diagnosis of nephrotic syndrome ( proteinuria ≥3.5 g/24h, and serum&#xD;
             albumin ≤30g/L ),&#xD;
&#xD;
          -  Pathological diagnosis with minimal change disease (MCD), focal segmental&#xD;
             glomerulosclerosis (FSGS) and podocyte disease&#xD;
&#xD;
          -  Serum creatinine &lt; 3mg/dl ( 265.2umol/L), estimated glomerular filtration rate(eGFR)&#xD;
             no less than 30 ml/min.1.73 m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who didn't sign written informed consent form&#xD;
&#xD;
          -  Patients who have received full-dose prednisone treatment for more than 2 weeks, or&#xD;
             pulsed methylprednisolone (&gt;7.5mg/kg.day) within 2 weeks&#xD;
&#xD;
          -  Patients who have taken immunosuppressants within 3 months, as Cyclosporine A,&#xD;
             Tacrolimus, Mycophenolate Mofetil, Cyclophosphamide, or Leflunomide etc.&#xD;
&#xD;
          -  Patients who have impaired liver function, with Alanine aminotransferase(ALT) or&#xD;
             Aspartate aminotransferase(AST) twice more than the normal upper limit, or who have&#xD;
             viral hepatitis B with hepatitis B e antigen(HBeAg) positive or hepatitis B virus DNA&#xD;
             (HBV-DNA) reduplicative&#xD;
&#xD;
          -  Patients who have contraindications to glucocorticoid, for example diabetes, obesity&#xD;
             (BMI&gt;28kg/m2 before disease onset), femoral head necrosis, or active infection.&#xD;
&#xD;
          -  Patients who have family history of kidney disease&#xD;
&#xD;
          -  Patients who have definite secondary facts of this disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhihong Liu, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Nanjing University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Institute of Nephrology</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 20, 2014</study_first_submitted>
  <study_first_submitted_qc>November 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2014</study_first_posted>
  <last_update_submitted>January 24, 2021</last_update_submitted>
  <last_update_submitted_qc>January 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanjing University School of Medicine</investigator_affiliation>
    <investigator_full_name>Zhi-Hong Liu, MD</investigator_full_name>
    <investigator_title>Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine</investigator_title>
  </responsible_party>
  <keyword>Prednisone</keyword>
  <keyword>idiopathic nephrotic syndrome</keyword>
  <keyword>prospective</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephrotic Syndrome</mesh_term>
    <mesh_term>Nephrosis</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

